Page 32 - NATIONAL ANTIBIOTIC RESISTANCE SURVEILLANCE REPORT 2021

Acinetobacter baumannii from blood specimens

Table 8: Percentage of antibiotic resistance for Acinetobacter baumannii isolated from blood.

The number of samples tested is stated in a bracket.

Antibiotic 2017 2018 2019 2020 2021
%R (no. tested) %R (no. tested) %R (no. tested) %R (no. tested) %R (no. tested)

Ampicillin/sulbactam 47.6 (1509) 48.9 (1578) 46.7 (1423) 54.4 (1409) 62.5 (2451)

Ceftazidime 51.7 (1607) 52.2 (1597) 51.6 (1319) 58.8 (1355) 68.3 (2347)

Imipenem 52.9 (1534) 54.3 (1553) 52.8 (1393) 59.3 (1421) 68.3 (2394)

Meropenem 53.6 (1574) 55.7 (1548) 54.4 (1346) 59.7 (1396) 69.9 (2386)

Gentamicin 46.2 (1560) 46.9 (1548) 45.3 (1416) 53.4 (1396) 60.8 (2334)

Amikacin 42.5 (1598) 43.2 (1588) 40.9 (1388) 48.2 (1436) 60.8 (2334)

Cefoperazone/ 40.1 (1162) 30.3 (1080) 29.6 (955) 26.5 (971) 56.7 (2413)
sulbactam
Ciprofloxacin 47.2 (1585) 46.3 (1587) 43.7 (1391) 47.2 (1361) 37.3 (1739)

The percentage of antibiotic resistance for Acinetobacter baumannii isolated from blood was relatively increased for all antibiotics tested

in 2021 compared to 2019 expect for ciprofloxacin which shows a decreased resistance rate from 47.2 % in 2020 to 37.3 % in 2021 (Table

8 and Figure 18).

28 |